These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36881059)

  • 21. Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database.
    Wakabayashi T; Hosohata K; Oyama S; Inada A; Ueno S; Kambara H; Iida T; Nakatsuji T; Uchida M; Iwanaga K
    Ther Clin Risk Manag; 2020; 16():741-747. PubMed ID: 32884275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
    Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Adverse Drug Reaction Risk in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
    Chisaki Y; Aoji S; Yano Y
    Biol Pharm Bull; 2017; 40(6):824-829. PubMed ID: 28566626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects.
    Nawa H; Hamano H; Niimura T; Miyata K; Yagi K; Goda M; Zamami Y; Ishizawa K
    Clin Transl Sci; 2022 Dec; 15(12):2982-2988. PubMed ID: 36128688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance.
    Wakabayashi T; Nakatsuji T; Kambara H; Niinomi I; Oyama S; Inada A; Ueno S; Uchida M; Iwanaga K; Iida T; Hosohata K
    Curr Rev Clin Exp Pharmacol; 2022; 17(2):144-148. PubMed ID: 33588740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance.
    Okada T; Hashiguchi M; Hori S
    Int J Clin Pharm; 2022 Dec; 44(6):1332-1341. PubMed ID: 36156764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
    Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
    J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central Nervous System Adverse Reactions to Amantadine Intoxication: A Case Report and Analysis of JADER.
    Ide N; Hosoya Y; Yamamoto M; Shigeno A; Obayashi M; Asada K; Matsushima S
    In Vivo; 2024; 38(4):2090-2096. PubMed ID: 38936887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality evaluation of the Japanese Adverse Drug Event Report database (JADER).
    Tsuchiya M; Obara T; Sakai T; Nomura K; Takamura C; Mano N
    Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):173-181. PubMed ID: 31823506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors and Hypothyroidism: An Analysis of the Japanese Pharmacovigilance Database.
    Tanaka H; Tani A; Onoda T; Ishii T
    In Vivo; 2024; 38(2):917-922. PubMed ID: 38418113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
    Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
    Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset.
    Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
    Life (Basel); 2022 Aug; 12(9):. PubMed ID: 36143391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database.
    Noda A; Sakai T; Obara T; Miyazaki M; Tsuchiya M; Oyanagi G; Murai Y; Mano N
    BMC Pharmacol Toxicol; 2020 May; 21(1):36. PubMed ID: 32448369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System.
    Suzuki S; Imai S; Mitsuboshi S; Kizaki H; Hashiguchi M; Hori S
    J Clin Pharmacol; 2023 Aug; 63(8):903-908. PubMed ID: 37042319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database.
    Sato J; Nakano K; Shimizu T; Uchida M
    Anticancer Res; 2022 Jul; 42(7):3575-3582. PubMed ID: 35790278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of adverse event profile of tacrolimus in patients with solid organ transplantation from a pharmacovigilance study.
    Kambara H; Oyama S; Inada A; Niinomi I; Wakabayashi T; Hosohata K
    Int J Clin Pharmacol Ther; 2021 Dec; 59(12):753-759. PubMed ID: 34402788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.